Amber Tong – Page 89 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test

6 years ago

La Jolla CEO decamps just as biotech faces a reckoning for iron overload drug

6 years ago

CymaBay scraps key NASH, PSC programs after lead drug triggers safety alarms — share price implodes

6 years ago

Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis

6 years ago

Aquestive nabs FDA OK for oral film version of generic ALS drug

6 years ago

With latest 18-month data cut, Takeda pushes toward 2021 launch of dengue vaccine — can they sidestep Sanofi's ...

6 years ago

Teaming up with NIH, ViiV buys into the next big thing in HIV: antibodies

6 years ago

New epilepsy company on the block wins FDA approval for made-in-Korea drug to treat focal seizures

6 years ago

Brii Bio backs infectious disease startup while inking deal for its lead TB drug, doubling down on antibiotics

6 years ago

AbbVie scoops up option to license Harpoon's BCMA drug for $50M upfront as biotech partner preps PhI/II trial

6 years ago

Eli Lilly touts $400M manufacturing expansion, 100 new jobs to much fanfare in Indianapolis — even though it's been ...

6 years ago

Amgen chops 172 more staffers in R&D, operations and sales amid neuroscience exit, revenue downturn

6 years ago

Here's a $25M seed fund aimed at backing some brash new drug ideas out of the Broad

6 years ago

Supreme Court turns down Martin Shkreli's latest appeal, leaving 'pharma bro' to 7-year sentence

6 years ago

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi ...

6 years ago

Dutch diagnostics player Qiagen confirms buyout talks following report of Thermo Fisher's interest

6 years ago

AstraZeneca gains EU nod for diabetes triple; Amgen and Duke launch real-world PCSK9 observational study

6 years ago

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront

6 years ago

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

6 years ago

Investors could emerge from Neil Woodford debacle with £1B loss, internal analysis reveals

6 years ago

Takeda doubles down on Finch's microbiome insights, signing up for a second project in Crohn's disease

6 years ago

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene is one step closer to China OK for PD-1

6 years ago

Flagship woos Novartis top dealmaker Prakash Raman in move to get the BD ball rolling early

6 years ago

ARCH-backed Chinese biotech scores PhIII win for glucokinase-modulating diabetes drug

6 years ago

First page Previous page 86 87 888990 91 92 Next page Last page